ftInvstr

HIKAL · Healthcare ₹225.0 +1.99% Mkt Cap ₹2752 Cr overvalued

HIKAL

Healthcare Drug Manufacturers - Specialty & Generic

★ Watchlist ⧉ Add to bucket

₹225.0

+1.99% today · 30d +5.58%

as of 2026-11-09

Price · Daily Candles

Detect candlestick pattern

AI narrative is temporarily unavailable for HIKAL. The deterministic sections below render from live data.

₹ Latest Earnings · Q ending 2025-12-31

REVENUE

₹494 Cr

+10.41% YoY

NET PROFIT

₹-6 Cr

-134.3% YoY

OPM

17.2%

+0.43pp YoY

EPS

₹-0.48

Intrinsic value · DCF ₹100.37 · Margin of safety -55.4% (overvalued) · FCF yield 5.2%

◇ Sector Position

PEERPEROCE %

HIKAL30.3110.0

SUNPHARMA37.7921.44

DIVISLAB93.121.56

ZYDUSLIFE28.424.22

+ 2 more peers — sign in to view

ML Forward Growth Predictions 🔒

9 ML-predicted forward-growth ranks across sales, EBIT, and FCF.

SCORE / 100

Overall

6-axis composite of the sections below.

Performance NEUTRAL 40

Valuation FAIR 40

Growth STEADY 64

Profitability DECENT 68

Technicals NEUTRAL 65

Risk LOW 70

Key Stats

P/B

2.37

52W HIGH

₹261.0

OFF HIGH

-13.79%

DIV YIELD

0.27%

MKT CAP

₹2752 Cr

◉ Active Signals

MACDBullish2.3306

RSI(14)Neutral57.92

Street Consensus

1 analyst

₹300.0

mean target

Low ₹300.0Now ₹225.0High ₹300.0

⧉ Strategy Fit 🔒

See which of ftInvstr's 50+ strategies hold HIKAL and at what entry.